---
title: "AppYea, Inc. | 10-Q: FY2025 Q2 Revenue: USD 1 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253520477.md"
datetime: "2025-08-18T21:02:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253520477.md)
  - [en](https://longbridge.com/en/news/253520477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253520477.md)
generator: "portal-rs"
---

# AppYea, Inc. | 10-Q: FY2025 Q2 Revenue: USD 1 K

Revenue: As of FY2025 Q2, the actual value is USD 1 K.

EPS: As of FY2025 Q2, the actual value is USD 0.

### Segment Revenue

-   Revenues for the three months ended June 30, 2025, were $1,000, compared to $2,000 for the same period in 2024. For the six months ended June 30, 2025, revenues were $4,000, compared to $15,000 in 2024.

### Operational Metrics

-   Gross profit (loss) for the three months ended June 30, 2025, was -$3,000, compared to -$1,000 in 2024. For the six months ended June 30, 2025, gross profit (loss) was -$4,000, compared to $9,000 in 2024.
-   Operating loss for the three months ended June 30, 2025, was -$353,000, compared to -$405,000 in 2024. For the six months ended June 30, 2025, operating loss was -$476,000, compared to -$803,000 in 2024.
-   Net profit (loss) for the three months ended June 30, 2025, was -$6,000, compared to $181,000 in 2024. For the six months ended June 30, 2025, net loss was -$172,000, compared to -$1,063,000 in 2024.

### Cash Flow

-   Net cash used in operating activities for the six months ended June 30, 2025, was $213,000, compared to $442,000 in 2024.
-   Net cash used in investing activities for the six months ended June 30, 2025, was $1,000, compared to $78,000 in 2024.
-   Net cash provided by financing activities for the six months ended June 30, 2025, was -$124,000, compared to -$456,000 in 2024.

### Future Outlook and Strategy

-   The company plans to file a 510(k) FDA submission for the AppySleep LAB app for the non-contact diagnosis of sleep apnea during 2026, and an FDA process for AppySleep PRO for the treatment of sleep apnea during 2027.
-   The company aims to establish its technology and related products as the gold standard for the targeted sectors over the next five years, focusing on developing a balanced and diverse pipeline of products and product candidates.
-   The company intends to maintain a global, diverse network of specialists to accelerate knowledge synergies and innovation, and establish distribution channels to maximize the commercial potential of its products.

### Related Stocks

- [APYP.US](https://longbridge.com/en/quote/APYP.US.md)
- [LOTT.US](https://longbridge.com/en/quote/LOTT.US.md)

## Related News & Research

- [Techlott Signs Definitive Five-Year Platform Agreement with The Gambia’s Exclusive Lottery and Gaming License Holder | APYP Stock News](https://longbridge.com/en/news/295677814.md)
- [AppYea Delays Annual 10-K Filing Briefly](https://longbridge.com/en/news/281286342.md)
- [APPYEA Inc. Announces Corporate Rebranding: Changes Name to TECHLOTT Inc. and Ticker Symbol to LOTT | LOTT Stock News](https://longbridge.com/en/news/288590945.md)
- [AppYea Delays Quarterly Filing Amid Strategic Shift](https://longbridge.com/en/news/286624185.md)
- [TechLott Q2 FY26 net loss widens to USD 1.87 million; revenue posts no revenue](https://longbridge.com/en/news/295943131.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**